TLX

Telix Pharmaceuticals Limited American Depositary Shares

16.21 USD
-0.50
2.99%
At close Apr 21, 4:00 PM EDT
1 day
-2.99%
5 days
-3.63%
1 month
-8.88%
3 months
-3.86%
6 months
7.00%
Year to date
8.07%
1 year
7.00%
5 years
7.00%
10 years
7.00%
 

About: Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Employees: 554

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

0% more ownership

Funds ownership: 0% [Q3] → 0% (+0%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$22
36%
upside
Avg. target
$22
36%
upside
High target
$22
36%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
UBS
Laura Sutcliffe
50% 1-year accuracy
1 / 2 met price target
36%upside
$22
Buy
Maintained
27 Jan 2025

Financial journalist opinion

Based on 10 articles about TLX published over the past 30 days

Positive
Benzinga
5 days ago
Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
Telix Pharmaceuticals Limited   TLX on Tuesday released preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study.
Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
Neutral
GlobeNewsWire
6 days ago
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study2.
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Positive
Zacks Investment Research
1 week ago
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Telix Pharmaceuticals Limited (TLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Positive
Zacks Investment Research
1 week ago
Telix Shares May Gain on the Distribution Deal With Cardinal Health
TLX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
Telix Shares May Gain on the Distribution Deal With Cardinal Health
Neutral
GlobeNewsWire
1 week ago
Telix Announces Cardinal Health for Gozellix Commercial Distribution
MELBOURNE, Australia and INDIANAPOLIS, April 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging1 agent for prostate cancer in the United States (U.S.).
Telix Announces Cardinal Health for Gozellix Commercial Distribution
Neutral
GlobeNewsWire
2 weeks ago
Telix Appoints Paul Schaffer as Chief Technology Officer
MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.
Telix Appoints Paul Schaffer as Chief Technology Officer
Positive
Seeking Alpha
2 weeks ago
Telix Pharmaceuticals: Building A Radiopharma Powerhouse
Telix Pharmaceuticals is leveraging its success with Illuccix to build a diversified theranostic platform, driving long-term value through strategic investments and regulatory wins. Strong financial performance, with 56% revenue growth and 70% EBITDA increase, supports aggressive reinvestment in late-stage assets and global infrastructure expansion. The pipeline includes promising candidates like Gozellix, Zircaix, and Pixclara, targeting prostate, kidney, and brain cancers, with potential multi-billion dollar market opportunities.
Telix Pharmaceuticals: Building A Radiopharma Powerhouse
Neutral
GlobeNewsWire
2 weeks ago
Anne Whitaker Appointed as Non-Executive Director
MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251.
Anne Whitaker Appointed as Non-Executive Director
Neutral
GlobeNewsWire
2 weeks ago
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
MELBOURNE, Australia, April 02, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase 1 ZOLAR1 trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the Melbourne Theranostic Innovation Centre (MTIC) in Melbourne, Australia.
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
Neutral
GlobeNewsWire
2 weeks ago
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®
BURNABY, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Telix ARTMS, Inc. (ARTMS), a global leader in radioisotope production technologies, is pleased to announce that the drug master file (DMF)1 for gallium-68 production using its QUANTM Irradiation System® (QIS®) cyclotron technology has been referenced for the first time with a United States (U.S.) Food and Drug Administration (FDA) approved product, with Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection).
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®
Charts implemented using Lightweight Charts™